Comparison of Old and New Systemic Treatments for Moderate to ...

Newer medications for AD including dupilumab, tralokinumab, lebrikizumab, and oral JAK inhibitors have been shown to be safe and efficacious.

Patients with moderate-to-severe AD and co-morbidities such as asthma may benefit from dupilumab, whereas patients with concurrent alopecia may ...

(PDF) Comparison of Old and New Systemic Treatments for ...

Newer treatments have shown significant efficacy with less side effects in clinical trials. This review discusses and compares conventional and ...

Effectiveness and safety of systemic therapy for moderate-to-severe ...

However, systemic therapies are rarely used in children because the natural disease course often leads to spontaneous improvement, and because ...

Systemic Immunomodulatory Treatments for Atopic Dermatitis

Minimal important differences were used to define important differences between medications. Certainty of evidence was assessed using the GRADE ...

Comparison of Old and New Systemic Treatments for Moderate to ...

Abstract Purpose of Review Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as ...

2-year results from PEDIatric STudy in Atopic Dermatitis

Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year ...

Systemic treatments for atopic dermatitis (eczema): Systematic ...

Previous systematic reviews of AD systemic therapies explored effects of specific agents or classes of medications on a limited number of ...

Biologic and Conventional Systemic Therapies Show Similar Safety ...

Within the elderly cohort, there was no significant difference in efficacy of biologics versus conventional systemics at any time point. Topical prescription ...

Systemic Immunomodulatory Treatments for Atopic Dermatitis

Since the publication of the initial review, new randomized clinical trials have been published, and we have continued to update our living ...

Systemic Treatments for Atopic Dermatitis: Which is Most Effective?

Dupilumab and cyclosporin are more effective systemic treatments for AD when compared with methotrexate among some patient populations.

Indirect comparison of deucravacitinib and other systemic treatments ...

Evidence suggests the comparative efficacy of systemic therapies may be different in Asian versus White patients. This systematic review and ...

Systemic Pharmacologic Treatments for Plaque Psoriasis - AAFP

When compared with each other, these medications had similar clinical effectiveness. Serious adverse events analysis was based on a very low number of events ...

Guidelines of care for the management of atopic dermatitis in adults ...

... medications. Furthermore, formal cost-effectiveness analyses comparing older to newer treatments are needed. As new systemic therapies ...

Comparative efficacy and safety of systemic therapies used in ...

Network meta-analyses (NMAs) can be used to synthesize available evidence on multiple treatments not been directly compared in a randomized ...

Systemic Therapy Advances for Atopic Dermatitis - Dermatology Times

Systemic therapy addition to topicals increased patient satisfaction and adherence in atopic dermatitis treatment compared to topicals-only.

Comparison of risankizumab and apremilast for the treatment of ...

... moderate psoriasis eligible for systemic therapy ... Patients aged ≥ 18 years were eligible if they had a diagnosis of moderate chronic plaque psoriasis ...

Systemic Therapy for Melanoma: ASCO Guideline Update

The Dummer et al 2021 trial reported improved recurrence-free survival (RFS) hazard ratio (HR) 0.75 (95% CI, 0.58 to 0.96), event-free survival (EFS) HR 0.58 ( ...

Investigative Report

Therefore, the aim of this study was to compare the choice of systemic treatments for patients with psoriasis between France (which had no available guidelines ...

Systemic Treatment - an overview | ScienceDirect Topics

The future of systemic therapies lies in the development of more specific and less toxic drugs, and the methods to best assess them. It also remains to be ...